Who are Conventional NSAA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Darolutamide Oral Tablet, Zoladex and Casodex, ODM-201 Tablet A, Maximum androgen blockade, Abiraterone Acetate or Enzalutamide, Proxalutamide (GT0918).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/conventional-nsaa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Conventional NSAA — Competitive Intelligence Brief

Conventional NSAA (Conventional NSAA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen receptor antagonist. Area: Oncology.

phase 3 Androgen receptor antagonist Androgen receptor (AR) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Conventional NSAA (Conventional NSAA) — University of Sydney. Conventional NSAA (non-selective androgen antagonist) blocks androgen receptor signaling to suppress testosterone-driven prostate cancer growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Conventional NSAA TARGET	Conventional NSAA	University of Sydney	phase 3	Androgen receptor antagonist	Androgen receptor (AR)
Darolutamide Oral Tablet	Darolutamide Oral Tablet	Santa Chiara Hospital	marketed	Androgen receptor antagonist	Androgen receptor (AR)
Zoladex and Casodex	Zoladex and Casodex	AstraZeneca	marketed	GnRH agonist (Zoladex) and androgen receptor antagonist (Casodex)	GnRH receptor (Zoladex); androgen receptor (Casodex)
ODM-201 Tablet A	ODM-201 Tablet A	Orion Corporation, Orion Pharma	marketed	Androgen receptor antagonist	Androgen receptor (AR)
Maximum androgen blockade	Maximum androgen blockade	Wonju Severance Christian Hospital	marketed	Androgen receptor antagonist combination therapy	Androgen receptor; testosterone synthesis pathway
Abiraterone Acetate or Enzalutamide	Abiraterone Acetate or Enzalutamide	National Cancer Institute, Naples	phase 3	Androgen synthesis inhibitor (abiraterone) / Androgen receptor antagonist (enzalutamide)	CYP17A1 (abiraterone) / Androgen receptor (enzalutamide)
Proxalutamide (GT0918)	Proxalutamide (GT0918)	Suzhou Kintor Pharmaceutical Inc,	phase 3	Androgen receptor antagonist	Androgen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen receptor antagonist class)

Santa Chiara Hospital · 2 drugs in this class
Cassiopea SpA · 2 drugs in this class
The First Affiliated Hospital with Nanjing Medical University · 2 drugs in this class
Pfizer · 2 drugs in this class
Suzhou Kintor Pharmaceutical Inc, · 1 drug in this class
AEterna Zentaris · 1 drug in this class
University of Sydney · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Orion Corporation, Orion Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Conventional NSAA — Competitive Intelligence Brief. https://druglandscape.com/ci/conventional-nsaa. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab